StrokeDx Nabs $5 Million in Seed Funding

StrokeDx now has the capacity to fund clinical validation and commercialization efforts for its stroke detection technology, having recently closed a $5 million in Series Seed Prime funding round.

Led by DigiTx Partners, the funding round also attracted Freeflow Ventures and other existing investors with accomplishments across neuroradiology, stroke, and medical devices. In conjunction with the funding round, DigiTx Partners Managing Director David J. Kim, M.D., will join StrokeDx’s board.

“We believe in the potential of StrokeDx’s technology to change the diagnostic paradigm and ultimately improve outcomes for stroke patients. By providing accessible, advanced technology, we can reach millions of at-risk individuals, potentially saving countless lives and reducing the burden on healthcare systems around the world,” Kim said.

To date, StrokeDx’s technology has raised almost $10 million, including a National Institutes of Health (NIH) R01 grant. This latest investment will support further clinical validation of StrokeDx’s technology and the expansion of its commercial efforts.
 
StrokeDx specializes in developing advanced technologies and software to enable portable, non-invasive, non-radiating cerebrovascular monitoring. The company’s approach offers a unique and highly precise method to survey strokes using next-generation technology developed by Shane Shahrestani, M.D., Ph.D., at the California Institute of Technology (Caltech). Blood contains a lot of ions that make it conductive. In ischemic stroke, a blocked artery prevents blood flow but in hemorrhagic stroke, there is too much blood in a certain area. By generating small magnetic fields, StrokeDx’s sensor works like a metal detector, and moving the sensor around the brain finds these areas of too much or too little blood flow. Early studies with the sensor have shown a diagnostic time between 1 and 2.5 minutes. 
 
The societal impact of StrokeDx’s technology is profound, offering a scalable solution to improve stroke outcomes for millions of at-risk individuals. By using portable devices, StrokeDx addresses critical issues in healthcare accessibility and equity. Stroke remains a leading cause of death and disability worldwide, and early detection and rapid monitoring are key to improving survival rates and quality of life.
 
“Stroke affects millions globally, leading to significant mortality and long-term disability. This funding enables us to scale our detection and monitoring solution, empowering physicians and their patients with an effective tool for point-of-care cerebrovascular monitoring. Early intervention can significantly reduce the impact of stroke, shifting the focus from treatment to prevention,” StrokeDx Co-Founder/CEO Alexander Ballatori stated. 
 
Pasadena, Calif.-based StrokeDx develops next-generation stroke detection technology.